JP2019516734A - 疼痛の治療 - Google Patents

疼痛の治療 Download PDF

Info

Publication number
JP2019516734A
JP2019516734A JP2018560846A JP2018560846A JP2019516734A JP 2019516734 A JP2019516734 A JP 2019516734A JP 2018560846 A JP2018560846 A JP 2018560846A JP 2018560846 A JP2018560846 A JP 2018560846A JP 2019516734 A JP2019516734 A JP 2019516734A
Authority
JP
Japan
Prior art keywords
par
compound
endosomal
signaling
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018560846A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516734A5 (https=
Inventor
バネット、ナイジェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016901912A external-priority patent/AU2016901912A0/en
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2019516734A publication Critical patent/JP2019516734A/ja
Publication of JP2019516734A5 publication Critical patent/JP2019516734A5/ja
Priority to JP2022000286A priority Critical patent/JP7441246B2/ja
Priority to JP2024022451A priority patent/JP2024073450A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2018560846A 2016-05-20 2017-05-19 疼痛の治療 Pending JP2019516734A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022000286A JP7441246B2 (ja) 2016-05-20 2022-01-04 疼痛の治療
JP2024022451A JP2024073450A (ja) 2016-05-20 2024-02-16 疼痛の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016901912 2016-05-20
AU2016901912A AU2016901912A0 (en) 2016-05-20 Treatment of Pain
PCT/AU2017/050469 WO2017197463A1 (en) 2016-05-20 2017-05-19 Treatment of pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022000286A Division JP7441246B2 (ja) 2016-05-20 2022-01-04 疼痛の治療

Publications (2)

Publication Number Publication Date
JP2019516734A true JP2019516734A (ja) 2019-06-20
JP2019516734A5 JP2019516734A5 (https=) 2020-06-25

Family

ID=60324618

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018560846A Pending JP2019516734A (ja) 2016-05-20 2017-05-19 疼痛の治療
JP2022000286A Active JP7441246B2 (ja) 2016-05-20 2022-01-04 疼痛の治療
JP2024022451A Pending JP2024073450A (ja) 2016-05-20 2024-02-16 疼痛の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022000286A Active JP7441246B2 (ja) 2016-05-20 2022-01-04 疼痛の治療
JP2024022451A Pending JP2024073450A (ja) 2016-05-20 2024-02-16 疼痛の治療

Country Status (9)

Country Link
US (1) US20190298743A1 (https=)
EP (1) EP3458062A4 (https=)
JP (3) JP2019516734A (https=)
CN (1) CN109152777A (https=)
AU (3) AU2017268039A1 (https=)
CA (1) CA3024719A1 (https=)
EA (1) EA201892672A1 (https=)
MX (2) MX395658B (https=)
WO (1) WO2017197463A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091524A1 (ru) * 2017-12-20 2020-09-16 Такеда Фармасьютикал Компани Лимитед Ингибиторы рецептора, активируемого протеазой 2
US20240066027A1 (en) 2020-12-03 2024-02-29 Domain Therapeutics Novel par-2 inhibitors
KR20250057699A (ko) 2022-06-03 2025-04-29 도메인 테라퓨틱스 신규한 par-2 억제제
WO2025172573A1 (en) 2024-02-16 2025-08-21 Domain Therapeutics Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025191185A1 (en) 2024-03-15 2025-09-18 Domain Therapeutics Azine-based compounds as par-2 inhibitors and therapeutic uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007532512A (ja) * 2004-04-08 2007-11-15 ヤード・テヒノロギース・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞膜ラフトと相互作用する構造を含む三者複合体およびその使用
US7541156B1 (en) * 2000-03-01 2009-06-02 Pasricha Pankaj J Method of identifying antinociceptive compounds using protease activated receptor-2
WO2009117481A1 (en) * 2008-03-19 2009-09-24 Regeneron Pharmaceuticals, Inc. Use of protease-activated receptor 2 antagonists
WO2015048245A1 (en) * 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106998A0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
CN1938013A (zh) * 2003-11-21 2007-03-28 纽卡斯尔大学研究协会有限公司 抑制发动蛋白依赖性的细胞内摄作用的方法和药剂
US20070225363A1 (en) * 2003-11-21 2007-09-27 The University Of Newcastle Research Associates Ltd. Methods and Agents for Inhibiting Dynamin-Dependent Endocytosis
EP2119455A1 (en) * 2004-04-08 2009-11-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tripartite raftophilic structures and their use
WO2009034464A2 (en) * 2007-09-12 2009-03-19 Newcastle Innovation Limited Indole related compounds with physiological activity
WO2013010218A1 (en) * 2011-07-15 2013-01-24 Freie Universität Berlin Inhibition of clathrin
CN115531553A (zh) * 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
AT518095B1 (de) * 2015-12-30 2018-01-15 Univ Wien Tech Verfahren zur Herstellung von ionischen Flüssigkeiten auf Basis des Bistriflimid-Anions
EA202091524A1 (ru) * 2017-12-20 2020-09-16 Такеда Фармасьютикал Компани Лимитед Ингибиторы рецептора, активируемого протеазой 2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541156B1 (en) * 2000-03-01 2009-06-02 Pasricha Pankaj J Method of identifying antinociceptive compounds using protease activated receptor-2
JP2007532512A (ja) * 2004-04-08 2007-11-15 ヤード・テヒノロギース・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞膜ラフトと相互作用する構造を含む三者複合体およびその使用
WO2009117481A1 (en) * 2008-03-19 2009-09-24 Regeneron Pharmaceuticals, Inc. Use of protease-activated receptor 2 antagonists
WO2015048245A1 (en) * 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GASTROENTEROLOGY, vol. Vol. 150, Issue 4, Suppl. 1, JPN6021020209, April 2016 (2016-04-01), pages 89, ISSN: 0004608016 *

Also Published As

Publication number Publication date
JP2022061998A (ja) 2022-04-19
NZ788380A (en) 2025-07-25
EP3458062A1 (en) 2019-03-27
JP7441246B2 (ja) 2024-02-29
JP2024073450A (ja) 2024-05-29
MX395658B (es) 2025-03-26
AU2023201732A1 (en) 2023-04-20
CN109152777A (zh) 2019-01-04
EP3458062A4 (en) 2020-01-15
CA3024719A1 (en) 2017-11-23
MX2022011564A (es) 2023-06-15
EA201892672A1 (ru) 2019-04-30
AU2025202933A1 (en) 2025-05-15
NZ748579A (en) 2025-07-25
AU2017268039A1 (en) 2018-12-06
MX2018014135A (es) 2019-06-17
US20190298743A1 (en) 2019-10-03
WO2017197463A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
JP7441246B2 (ja) 疼痛の治療
US20230119819A1 (en) Tripartite Modulators of Endosomal G Protein-Coupled Receptors
Tang et al. TRPC channels blockade abolishes endotoxemic cardiac dysfunction by hampering intracellular inflammation and Ca2+ leakage
WO2021231208A1 (en) Methods of treating covid-19 using bardoxolone methyl or analogs thereof
US20220401435A1 (en) Mrgprx2 antagonist for the treatment of pseudo allergic reactions
JP7676323B2 (ja) Ｇｐｃｒヘテロマー阻害剤及びその使用
US20250064892A1 (en) Use of soluble pro(renin) receptor to treat metabolic disorders and related conditions
JP2016132619A (ja) アルツハイマー病治療剤
EP1512016B1 (en) Screening method and anti-tumor drug candidate obtained therefrom
JP4896870B2 (ja) 細胞膜ラフトと相互作用する構造を含む三者複合体およびその使用
US20200206299A1 (en) Inhibitors of beta-arrestin-neurokinin 1 receptor interactions for the treatment of pain
US7897401B2 (en) Control of apoptosis by controlling the propensity of ceramide channel formation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210823

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220104

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220104

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220118

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220207

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220208

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220304

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220308

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230328

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230404